View Filing Data

Cash, Cash Equivalents, and Marketable Securities [Text Block]

Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	December 31, 2014
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Certificate of deposits	$	249.0	$	—	$	—	$	249.0
Money market funds	12,791.9		—		—		12,791.9
Municipal debt securities	9,317.3		1.3		—		9,318.6
Total	$	22,358.2	$	1.3	$	—	$	22,359.5

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):



	December 31, 2014
Cash and cash equivalents	$	15,279.4
Marketable securities	7,080.1
Total	$	22,359.5

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	December 31, 2014
	Amortized Cost		Estimated Fair Value
Less than one year	$	22,358.2	$	22,359.5
Greater than one year	—		—
Total	$	22,358.2	$	22,359.5

Deferred Costs	12 Months Ended
Deferred Costs	Dec. 31, 2014
Inventories [Abstract]
Inventory Disclosure [Text Block]	Deferred Costs Deferred costs representing work in process for costs incurred on process development contracts that have not been completed, were $2.6 million and $1.3 million as of December 31, 2014 and December 31, 2013, respectively. The Company also has deferred revenue of approximately $3.9 million and $1.5 million of progress billings received as of December 31, 2014 and December 31, 2013, respectively, related to these contracts.

Property, Plant & Equipment

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

Property, Plant and Equipment

Property, plant, and equipment consisted of the following (in thousands):



	December 31,
	2014			2013
Building and improvements	$	11,298.7		$	11,229.9
Machinery and equipment	68.3			58.2
Lab equipment	6,324.7			2,743.7
Furniture and fixtures	1,166.3			958.0
Software	312.4			203.1
Leasehold improvements	2,219.6			674.1
Property, plant and equipment, gross	21,390.0			15,867.0
Accumulated depreciation	(5,429.3		)	(3,022.8		)
Property, plant and equipment, net	$	15,960.7		$	12,844.2

The Company’s results included depreciation expense of approximately $1.6 million, $1.0 million and $1.0 million for the years ended December 31, 2014, 2013, and 2012, respectively.

Loss Per Share

12 Months Ended

Dec. 31, 2014

Loss Per Share [Abstract]

Loss Per Share [Text Block]

Loss Per Share

For the years ended December 31, 2014, 2013, and 2012 the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share as they are anti-dilutive in the periods presented. At December 31, 2014, 2013, and 2012 the Company excluded the following potentially dilutive securities:



	December 31,
	2014	2013	2012
Stock Options	4,427,276	2,932,191	2,168,668
Warrants	3,550,956	4,898,266	5,528,761
Restricted Shares	280,481	78,500	34,250

ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]

At December 31, 2014, 2013, and 2012 the Company excluded the following potentially dilutive securities:



	December 31,
	2014	2013	2012
Stock Options	4,427,276	2,932,191	2,168,668
Warrants	3,550,956	4,898,266	5,528,761
Restricted Shares	280,481	78,500	34,250

Fair Value Measurements

12 Months Ended

Dec. 31, 2014

Fair Value Measurements [Abstract]

Fair Value Measurements [Text Block]

Fair Value Measurements

Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The Company classifies the fair value of the warrant derivative liabilities as level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows. In May 2014, the warrants expired and the value of the warrant derivative liabilities were written off and recorded in other expenses in our consolidated statement of operations.

The Company classifies the fair value of contingent consideration obligations as level 3 inputs. The Company has recognized contingent consideration obligations related to the following:

•

In October 2011, in connection with the Company's acquisition of Amorcyte, contingent consideration obligations were recognized relating to earn out payments equal to 10% of the net sales of the lead product candidate NBS10 (in the event of and following the date of first commercial sale of NBS10), provided that in the event NeoStem sublicenses NBS10, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that NeoStem will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”). The contingent consideration fair value decreased from $9.5 million as of December 31, 2013 to $5.5 million as of December 31, 2014. The change in estimated fair value is based primarily on the Company's updates to the discounted cash flow model using a probability-weighted income approach subsequent to the reporting of the primary analysis from the Preserve AMI Phase 2 clinical trial in the fourth quarter of 2014, and has been recorded in other expenses in our consolidated statement of operations.

•

In May 2014, in connection with the Company's acquisition of CSC, contingent consideration obligations were recognized relating to milestone payments of up to $90 million, based on the achievement of certain milestones associated with the future development of the acquired programs. The contingent consideration fair value recognized in the acquisition in May 2014 was $11.9 million. The contingent consideration fair value increased to $12.8 million as of December 31, 2014. The change in estimated fair value is based on changes in assumptions regarding the timing of certain milestone achievements, as well as the time progression to reach those milestones as of December 31, 2014, and has been recorded in other expenses in our consolidated statement of operations.

The fair value of contingent consideration obligations is based on discounted cash flow models using a probability-weighted income approach. The measurements are based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The Company bases the timing to complete the development and approval programs on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2014, and December 31, 2013 (in thousands):



	December 31, 2014								December 31, 2013
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	7,080.0	$	—	$	7,080.0	$	—	$	—	$	—	$	—
	$	—	$	7,080.0	$	—	$	7,080.0	$	—	$	—	$	—	$	—

Liabilities:
Warrant derivative liabilities	—		—		—		—		—		—		23.2		23.2
Contingent consideration	—		—		18,260.0		18,260.0		—		—		9,450.0		9,450.0
	$	—	$	—	$	18,260.0	$	18,260.0	$	—	$	—	$	9,473.2	$	9,473.2

There were no transfers of financial instruments to or from Levels 1, 2 or 3 during the periods presented. For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the year ended December 31, 2014 by type of instrument (in thousands):



	Year Ended
	December 31, 2014
	Warrants			Contingent Consideration			Total
Beginning liability balance	$	23.2		$	9,450.0		$	9,473.2

Amount issued in acquisition	—			11,890.0			11,890.0
Change in fair value recorded in operations	—			(3,080.0		)	(3,080.0		)
Expiration	(23.2		)	—			(23.2		)

Ending liability balance	$	—		$	18,260.0		$	18,260.0

Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts receivable, and accounts payable.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Goodwill and Other Intangible Assets [Abstract]

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets [Text Block]

Goodwill and Other Intangible Assets

The following table summarizes the changes in the carrying amount of goodwill (in thousands):



	Total
Balance as of December 31, 2013	$	11,117.8
Goodwill resulting from the acquisition of CSC	14,091.5
Balance as of December 31, 2014	$	25,209.3

The Company's intangible assets and related accumulated amortization as of December 31, 2014 and December 31, 2013 consisted of the following (in thousands):



		December 31, 2014							December 31, 2013
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(395.1	)	$	604.9	$	1,000.0	$	(295.1	)	$	704.9
Manufacturing technology	10 years	3,900.0		(1,540.9		)	2,359.1		3,900.0		(1,150.9		)	2,749.1
Tradename	10 years	800.0		(316.1		)	483.9		800.0		(236.1		)	563.9
In process R&D	Indefinite	43,690.0		—			43,690.0		9,400.0		—			9,400.0
Patent rights	19 years	669.0		(246.5		)	422.5		669.0		(211.3		)	457.7
Total Intangible Assets		$	50,059.0	$	(2,498.6	)	$	47,560.4	$	15,769.0	$	(1,893.4	)	$	13,875.6

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Year Ended December 31,
	2014		2013		2012
Cost of revenue	$	316.8	$	390.0	$	390.0
Research and development	108.4		35.2		35.2
Selling, general and administrative	180.0		180.0		180.0
Total	$	605.2	$	605.2	$	605.2

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):



2015	$	605.2
2016	605.2
2017	605.2
2018	605.2
2019	605.2
Thereafter	44,534.4
	$	47,560.4

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Liabilities

12 Months Ended

Dec. 31, 2014

Accrued Liabilities [Abstract]

Accrued Liabilities

Accrued liabilities were as follow (in thousands):



	December 31,
	2014		2013
Salaries, employee benefits and related taxes	$	2,807.2	$	2,325.8
Professional fees	495.4		544.8
License fees	—		500.0
Other	1,020.3		647.4
	$	4,322.9	$	4,018.0

Debt

12 Months Ended

Dec. 31, 2014

Debt [Abstract]

Debt Disclosure [Text Block]

Debt

Notes Payable

As of December 31, 2014 and December 31, 2013, the Company had notes payable of approximately $1.6 million and $0.9 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years.

Long-Term Debt

On September 26, 2014, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (together with its successors and assigns, the “Lender”) pursuant to which the Lender has agreed to lend the Company up to $20.0 million. Upon entering into the Loan and Security Agreement, the Lender disbursed $15.0 million (“Term Loan A”). Under the terms of the Loan and Security Agreement, during the Second Draw Period (as defined below), the Company may, subject to certain conditions, borrow from Lender an additional $5.0 million (“Term Loan B”, together with Term Loan A, the “Term Loans”). The “Second Draw Period” is the period of time: (a) commencing on the date that Lender receives evidence in a form and substance satisfactory to Lender that the Company has entered into a strategic arrangement with respect to the Company’s NBS10 product candidate for ST Elevation Myocardial Infarction and receives an upfront payment of not less than $10.0 million in connection therewith, and (b) ending on the earlier of September 19, 2015 or the occurrence of an event of default under the Term Loans. After repayment of all outstanding amounts due under two loans from TD Bank, N.A. in the amount of approximately $3.1 million, and deductions for debt offering/issuance costs and interim period interest, the net proceeds from Term Loan A were $11.3 million. The debt offering/issuance costs have been recorded as debt issuance costs in other assets in the consolidated balance sheet, and will be amortized to interest expense throughout the life of the Term Loans using the effective interest rate method. The proceeds from the Term Loans may be used to satisfy the Company’s future working capital needs, including the development of its cell therapy product candidates.

The Company will make interest only payments on the outstanding amount of Term Loans on a monthly basis until October 1, 2015 at a rate of 8.50% per annum; provided however, such interest-only period may be extended to April 1, 2016, in the event of either (1) the signing of a partnership for (x) traumatic brain injury indication for the Company's Ischemic Repair Program or for its VSEL^TM Program or (y) critical limb ischemia indication for its Ischemic Repair Program; or (2) the initiation of the Intus Phase 3 study evaluating the Company's product candidate NBS20 (also referred to as DC/TC) in patients with Stage IV or recurrent Stage III metastatic melanoma. Commencing on the date that principal payments commence, the Company will make consecutive monthly payments of principal and interest based upon a repayment schedule equal to (a) 36 months, if the Term Loans begin amortizing on October 1, 2015, or (b) 30 months, if the Term Loans begin amortizing on April 1, 2016. The Term Loans mature on September 1, 2018. At its option, the Company may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest), subject to a prepayment fee that is determined based on the date the loan is prepaid. The Company is also required to pay Lender a final payment fee equal to 8% of the Term Loan A and Term Loan B (if disbursed). The final payment fee will be amortized to interest expense throughout the life of the Term Loans using the effective interest rate method. The Company paid a facility fee in the amount of $100,000 in connection with Term Loan A.

Under the Loan and Security Agreement and a related mortgage, the Company granted to Lender a security interest in all of the Company’s real property and personal property now owned or hereafter acquired, excluding intellectual property, and certain other assets and exemptions. The Company also entered into a Mortgage and Absolute Assignment of Leases and Rents (the "Mortgage"). The Company also granted Lender a security interest in the shares of the Company’s subsidiaries. The Loan and Security Agreement restricts the ability of the Company to: (a) convey, lease, sell, transfer or otherwise dispose of any part of its business or property; and (b) incur any additional indebtedness. The Loan and Security Agreement provides for standard indemnification of Lender and contains representations, warranties and certain covenants of the Company. Upon the occurrence of an event of default by the Company under the Loan and Security Agreement, Lender will have customary acceleration, collection and foreclosure remedies. There are no financial covenants associated with the Loan and Security Agreement. As of December 31, 2014, the Company was in compliance with all covenants under the Loan and Security Agreement.

Estimated future principal payments, interest, and fees due under the Loan and Security Agreement are as follows:



Years Ending December 31,	(in millions)
2015	$	2.4
2016	5.7
2017	5.7
2018	5.4
Total	$	19.2

During the year ended December 31, 2014, the Company recognized $0.3 million of interest expense related to the Loan and Security Agreement.

Mortgages Payable

In October 2007, PCT issued a note to borrow $3.1 million (the “First Mortgage”) in connection with its $3.8 million purchase of condominium units in an existing building in Allendale, New Jersey (the “Property”). The First Mortgage was payable in 239 consecutive monthly payments of principal and interest, based on a 20 year amortization schedule; and one final payment of all outstanding principal plus accrued interest then due. The monthly installment was $20,766, which includes interest at an initial rate of 5.00%; the interest rate and monthly installments payments were subject to adjustment on October 1, 2017. The outstanding balance was approximately $2.5 million at December 31, 2013. In connection with the Loan and Security Agreement signed in September 2014, the remaining mortgage obligation was repaid, along with accrued interest and mortgage termination fees.

In December 2010 PCT Allendale, a wholly-owned subsidiary of PCT, entered into a note for a second mortgage in the amount of $1 million (the "Second Mortgage") on the Allendale Property with TD Bank, N.A. The initial guarantors of the Second Mortgage were PCT, DomaniCell (a wholly-owned subsidiary of PCT, now known as NeoStem Family Storage, LLC), Regional Cancer Care Associates LLC and certain of its partners. The Second Mortgage was for124 months at a fixed rate of 6% for the first 64 months. The outstanding balance was approximately $0.8 million at December 31, 2013. In connection with the Loan and Security Agreement signed in September 2014, the remaining mortgage obligation was repaid, along with accrued interest and mortgage termination fees.

Prior to the full repayment of the mortgages in September 2014, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A. in December 2013, whereby prior guarantors were released (see Note 16) and replaced with NeoStem, PCT, and NeoStem Family Storage, LLC.

Shareholders' Equity

12 Months Ended

Dec. 31, 2014

Shareholders’ Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Stockholders' Equity

Reverse Stock Split

On June 28, 2013, pursuant to prior shareholder authorization, the Company’s board of directors unanimously approved a 1-for-10 reverse stock split of the Company’s common stock, which the Company effected on July 16, 2013. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the reverse stock split. The shares of common stock retained a par value of $0.001 per share. Accordingly, the stockholders’ deficit reflects the reverse stock split by reclassifying from “common stock” to “Additional paid-in capital” an amount equal to the par value of the decreased shares resulting from the reverse stock split.

Equity Plans

The Company's 2003 Equity Participation Plan (the “2003 Equity Plan”) expired in 2013 and accordingly, equity awards under the 2003 Equity Plan can no longer be issued. The Company's 2009 Equity Compensation Plan (the “2009 Equity Plan”) makes up to 8,995,000 shares of common stock of the Company (as of December 31, 2014) available for issuance to employees, consultants, advisors and directors of the Company and its subsidiaries pursuant to incentive or non-statutory stock options, restricted and unrestricted stock awards and stock appreciation rights.

All stock options under the 2003 Equity Plan were granted and the 2009 Equity Plan are granted at the fair market value of the common stock at the grant date. Stock options vest either on the date of grant, ratably over a period determined at time of grant, or upon the accomplishment of specified business milestones, and generally expire 2, 3, or 10 years from the grant date depending on the status of the recipient as a consultant, employee or director of the Company.

The 2009 Equity Plan was originally adopted by the stockholders of the Company on May 8, 2009. On October 29, 2009, the stockholders of the Company approved an amendment to the 2009 Equity Plan to increase the number of shares of common stock available for issuance thereunder from 380,000 to 975,000. At the 2010 Annual Meeting of Stockholders of the Company held on June 2, 2010, the stockholders approved an amendment to increase this number to 1,375,000. At a Special Meeting of Stockholders of the Company held on January 18, 2011, the stockholders approved an amendment to increase this number to 1,775,000. At the 2011 Annual Meeting of Stockholders of the Company held on October 14, 2011, the stockholders approved an amendment to increase this number to 2,375,000. At the 2012 Annual Meeting of Stockholders of the Company held on October 5, 2012, the stockholders approved an amendment to (i) merge the 570,000 shares reserved for issuance under the Company's 2009 Non-U.S. Based Equity Compensation Plan (the "Non-U.S. Plan") with and into the 2009 Equity Plan, and (ii) increase by 450,000 the aggregate number of shares authorized for issuance under the 2009 Equity Plan (the “2009 Amended & Restated Equity Plan”). At the Company's 2013 Annual Meeting held October 3, 2013, the Company's stockholders approved an amendment to the 2009 Amended & Restated Equity Plan to increase the number of shares authorized for issuance to 5,995,000. At the Company's 2014 Annual Meeting held October 6, 2014, the Company's stockholders approved an amendment to the 2009 Amended & Restated Equity Plan to increase the number of shares authorized for issuance to 8,995,000.

The number of remaining shares authorized to be issued under the various equity plans are as follows:



	2003 Equity Plan		2009 Equity Plan
Shares Authorized for Issuance	250,000		8,995,000
Outstanding Stock Options	(122,395	)	(4,304,881	)
Exercised Stock Options	(9,250	)	(80,856	)
Restricted stock or equity grants issued under Equity Plans	(88,993	)	(946,711	)
Shares Expired	(29,362	)	—
Total common shares remaining to be issued under the Equity Plans	—		3,662,552

The Company adopted an employee stock purchase plan effective January 1, 2013, and authorized 500,000 shares under the plan. The plan has two six-month offering periods per year under which eligible employees may contribute up to 15% of their compensation toward the purchase of the Company's common stock per offering period (with a $25,000 cap per calendar year). The employee's purchase price is equal to (i) 85% of the closing price of a share of the Company's common stock on the enrollment date of such offering period or (ii) 85% of the closing price of a share of the Company's Common Stock on the Exercise Date of such Offering Period, whichever is lower. During the year ended December 31, 2014, 65,441 shares were issued under the employee stock purchase plan. At December 31, 2014, the Company had 434,559 shares of the Company's common stock available for future grant in connection with this plan.

Equity Issuances

In September 2011, the Company entered into a common stock Purchase Agreement (the “Initial Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provided that Aspire Capital was committed to purchase up to an aggregate of $20.0 million worth of shares of the Company’s common stock over the 24-month term. In August, 2012, the Initial Purchase Agreement was extended for an additional 24-month term through September 2015. During the three months ended March 31, 2014, the Company issued 0.8 million shares of Common Stock under the provisions the Initial Purchase Agreement for gross proceeds of approximately $5.6 million. As a result, the full $20.0 million worth of shares of the Company's stock have been issued under the Initial Purchase Agreement.

In March 2014, the Company entered into a new common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital, which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30.0 million worth of shares of the Company’s common stock over the 24-month term. At the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price and other requirements are met. The purchase price for the shares of stock is based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of Volume Weighted Average Price purchases), in each case as determined by parameters defined in the Purchase Agreement. As consideration for entering into the Purchase Agreement, we issued 150,000 shares of our common stock to Aspire Capital. During the year ended December 31, 2014, the Company issued 1.6 million shares of Common Stock under the provisions of the Purchase Agreement with Aspire for gross proceeds of approximately $10.9 million. As of December 31, 2014, the remaining amount available to the Company under the Purchase Agreement was $19.1 million.

Option Exercises

During the year ended December 31, 2014, option holders exercised an aggregate of 48,987 options at exercise prices between $5.20 and $6.20 per share for gross proceeds of approximately $0.3 million.

Warrant Exercises

During the year ended December 31, 2014, warrant holders exercised an aggregate of 333,250 warrants at an exercise price of $5.16 per share for gross proceeds of approximately $1.7 million.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the years ended December 31, 2014 and December 31, 2013:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2013	2,932,191		$	11.19	6.81 years	$	1,658.1	4,898,266		$	16.50	2.63	$	1,811.0

Changes during the Year:
Granted	2,265,850		$	6.72				2,722		$	12.26
Exercised	(48,987	)	$	5.53				(333,250	)	$	5.16
Forfeited	(368,704	)	$	6.78				(100,108	)	$	70.00
Expired	(353,116	)	$	12.94				(916,674	)	$	23.95
Outstanding at December 31, 2014	4,427,234		$	9.19	6.93	$	28.6	3,550,956		$	14.12	2.12	$	1.0
Vested at December 31, 2014 or expected to vest in the future	4,253,465		$	9.28	6.84	$	27.0	3,550,956		$	14.12	2.12	$	1.0
Exercisable at December 31, 2014	2,968,379		$	10.22	6.11	$	16.6	3,543,456		$	14.13	2.12	$	1.0

The total intrinsic value of stock options exercised during the years ended December 31, 2014 and December 31, 2013 was $61,641 and $104,360, respectively.

During the years ended December 31, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data):



	Year Ended December 31,
	2014		2013
Number of Common Stock Purchase Warrants Issued	—		40,407
Value of Common Stock Purchase Warrants Issued	$	—	$	149.9

Restricted Stock

During the years ended December 31, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data):




	2014		2013
Number of Restricted Stock Issued	917,907		514,700
Value of Restricted Stock Issued	$	4,996.3	$	3,360.0

The weighted average estimated fair value of restricted stock issued for services in the years ended December 31, 2014 and 2013 was $5.44 and $6.53 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally within one year.

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Share-Based Compensation (Notes)

12 Months Ended

Dec. 31, 2014

Share-based Compensation [Abstract]

Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants and restricted stock. The following table summarizes the components of share-based compensation expense for the years ended December 31, 2014 and 2013 ($ in thousands):



	Year Ended December 31,
	2014		2013		2012
Cost of revenues	$	494.2	$	314.0	$	195.0
Research and development	2,058.2		822.2		432.9
Selling, general and administrative	8,657.1		5,702.5		6,084.6
Total share-based compensation expense	$	11,209.5	$	6,838.7	$	6,712.5

Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December 31, 2014 were as follows ($ in thousands):



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	4,598.4	$	7.2	$	528.6
Expected weighted-average period in years of compensation cost to be recognized	3.79		0.54		0.31

Total fair value of shares vested and the weighted average estimated fair values of shares grant for the year ended December 31, 2014, 2013, and 2012 were as follows ($ in thousands):



	Stock Options						Warrants
	Year Ended December 31,						Year Ended December 31,
	2014		2013		2012		2014		2013		2012
Total fair value of shares vested	$	5,387.1	$	3,375.7	$	5,408.0	$	9.6	$	129.0	$	171.6
Weighted average estimated fair value of shares granted	4.56		4.29		3.63		—		3.71		4.10

Valuation Assumptions

The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

The range of assumptions made in calculating the fair values of stock options and warrants was as follow:



	Stock Options						Warrants
	Year Ended December 31,						Year Ended December 31,
	2014		2013		2012		2014		2013		2012
Expected term - minimum (in years)	0		1		2		3		2		2
Expected term - maximum (in years)	10		10		10		3		5		5
Expected volatility - minimum	62%		61%		73%		66%		73%		76%
Expected volatility - maximum	77%		79%		84%		66%		79%		83%
Weighted Average volatility	74	%	72	%	83	%	66	%	74	%	82	%
Expected dividend yield	—		—		—		—		—		—
Risk-free interest rate - minimum	0.12%		0.13%		0.28%		0.79%		0.32%		0.27%
Risk-free interest rate - maximum	3.00%		2.67%		1.99%		0.79%		1.73%		0.88%

Income Taxes

12 Months Ended

Dec. 31, 2014

Income Taxes [Abstract]

Income Tax Disclosure [Text Block]

Income Taxes

The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):



	Years Ended December 31,
	2014			2013			2012
United States	$	(55,570.4	)	$	(38,705.2	)	$	(36,276.9	)
	$	(55,570.4	)	$	(38,705.2	)	$	(36,276.9	)

The provision (benefit) for income taxes was as follows ($ in thousands):



		Years Ended December 31,
		2014			2013		2012
Current
	US Federal	$	—		$	—	$	—
	State and local	—			—		—
		$	—		$	—	$	—
Deferred
	US Federal	$	159.0		$	476.9	$	—
	State and local	(263.2		)	303.2		(175.5		)
		$	(104.2	)	$	780.1	$	(175.5	)
Total
	US Federal	$	159.0		$	476.9	$	—
	State and local	(263.2		)	303.2		(175.5		)
		$	(104.2	)	$	780.1	$	(175.5	)

The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 34% to income before income taxes as a result of the following ($ in thousands):



	Years Ended December 31,
	2014			2013			2012
U.S. Federal benefit at statutory rate	$	(18,894.0	)	$	(13,159.8	)	$	(12,334.1	)
State and local benefit net of U.S. federal tax	(3,435.0		)	(3,430.9		)	(2,154.1		)
Permanent non deductible expenses for U.S. taxes	1,094.6			1,798.2			(2,781.4		)
True-up of prior year net operating loss	(25.5		)	(91.4		)	321.6
Return to actual	—			(3,822.9		)	(384.8		)
Foreign earnings not permanently reinvested	—			—			(1,810.3		)
Effect of change in deferred tax rate	1,075.7			(1,094.8		)	525.7
Valuation allowance for deferred tax assets	20,080.0			20,581.7			18,441.9
Tax provision	$	(104.2	)	$	780.1		$	(175.5	)

Deferred income taxes at December 31, 2014, 2013 and 2012 consist of the following ($ in thousands):



	December 31,
	2014			2013			2012
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$	69,047.0		$	43,334.8		$	25,727.7
Deferred revenue	—			10.5			23.1
Contingent accounts payable	(7.8		)	13.6			15.2
Share-based compensation	9,577.2			7,971.9			5,466.7
Intangibles	715.1			704.6			287.3
Accumulated depreciation	—			—			348.7
Charitable contributions	409.8			414.9			391.8
Bad debt provision	296.9			304.3			239.7
Capital loss carry-forward	6,925.1			7,036.8			6,644.5
Other	609.7			—			—
Deferred tax assets prior to tax credit carryovers	87,573.0			59,791.4			39,144.7

Deferred Tax Liabilities:
Accumulated depreciation	$	(18.8	)	$	(64.8	)	$	—
Intangible and indefinite lived assets	(18,176.3		)	(4,379.2		)	(3,599.1		)
Deferred tax liabilities	(18,195.1		)	(4,444.0		)	(3,599.1		)
	69,377.9			55,347.4			35,545.6
Valuation reserve	(87,554.1		)	(59,726.6		)	(39,144.7		)
Net deferred tax liability	$	(18,176.2	)	$	(4,379.2	)	$	(3,599.1	)

In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.

As of December 31, 2014 and 2013, the Company had approximately $177.2 million and $110.6 million, respectively of Federal NOLs available to offset future taxable income expiring from 2025 through 2033. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. If a change of ownership did occur there would be an annual limitation on the usage of the Company’s losses which are available through 2032.

The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.

As of December 31, 2014, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

The Federal tax returns are currently being audited for the years 2012 and 2013. For years prior to 2011 the federal statute of limitations is closed. Most of the remaining states remain open to examination for a period of 3 to 4 years from date of filing. The Company files tax returns in all of the foreign jurisdictions that it has a permanent establishment and the tax filings remain subject to examination for 4 to 5 years.

Discontinued Operations

12 Months Ended

Dec. 31, 2014

Discontinued Operations [Abstract]

Discontinued Operations [Text Block]

Discontinued Operations

Regenerative Medicine - China segment

In the first quarter of 2012, the Company exited its regenerative medicine business in the People's Republic of China. As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):



Cash	$	195.1
Prepaid expenses and other current assets	14.9
Property, plant and equipment, net	1,023.7
Other Assets	330.5
Accounts payable	(177.1		)
Accrued liabilities	(79.2		)
Accumulated comprehensive income	(169.9		)
Loss on exit of segment	$	1,138.0

The operations and cash flows of the Regenerative Medicine - China business were eliminated from ongoing operations as a result of our exit decision, and the Company will not have continuing involvement in this business going forward. The operating results of the Regenerative Medicine – China business for the year ended December 31, 2012, which are included in discontinued operations, were as follows (in thousands):



	Year Ended December 31,
	2012
Revenue	$	52.3
Cost of revenues	(30.6		)
Research and development	(103.3		)
Selling, general, and administrative	(497.3		)
Other income (expense)	(6.8		)
Loss on exit of segment	(1,138.0		)
Loss from discontinued operations	$	(1,723.7	)

Pharmaceutical Manufacturing - China segment

On November 13, 2012, the Company completed the divestiture of its 51% interest (the “Erye Interest”) in Suzhou Erye Pharmaceuticals Company Ltd., a Sino-foreign equity joint venture with limited liability organized under the laws of the People's Republic of China. Pursuant to the Equity Purchase Agreement, the aggregate purchase price paid to the Company for the Erye Interest consisted of (i) approximately $12.3 million in cash, (ii) the return to the Company of 104,000 shares of NeoStem common stock and (iii) the cancellation of 117,000 options and 64,000 warrants to purchase our common stock. The fair value of the shares was based on the Company's closing price on the date of sale, and was recorded as Treasury Stock in our balance sheet. The fair values of the canceled options and warrants were based on the Black-Scholes values on the date of sale, and were recorded against Additional Paid in Capital in the accompanying balance sheet. The Company recognized the following loss on the date of sale of its 51% interest in Erye (in thousands):



Fair value of consideration received	$	13,397.9
Carrying value of segment non-controlling interest	6,015.0
Carrying value of segment accumulated comprehensive income	4,387.4
	$	23,800.3
Less carrying amount of assets and liabilities sold:
Cash	$	8,457.5
Restricted Cash	2,918.1
Accounts Receivable	6,130.2
Inventories	15,077.7
Prepaid expenses and other current assets	957.8
Property, plant and equipment, net	38,102.0
Other assets	5,946.3
Accounts payable	(9,604.8		)
Accrued liabilities	(2,008.8		)
Bank loans	(15,133.5		)
Notes payable	(6,599.3		)
Other liabilities	(9,166.8		)
Amount due related party	(7,859.7		)
	$	27,216.7

Loss on exit of segment	$	(3,416.4	)

The operations and cash flows of the Pharmaceutical Manufacturing - China business were eliminated from ongoing operations with the sale of the Company's Erye Interest. The operating results of the Pharmaceutical Manufacturing - China business for the year ended December 31, 2012, which are included in discontinued operations, were as follows (in thousands):



	Year Ended December 31,
	2012
Revenue	$	61,703.1
Cost of revenues	(40,245.2		)
Research and development	(1,836.4		)
Selling, general, and administrative	(10,740.0		)
Other expense	(1,045.2		)
Provision for income taxes	(1,794.1		)
Asset impairments	(31,170.1		)
Loss on sale of segment	(3,416.4		)
Loss from discontinued operations	$	(28,544.3	)

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

+ Details

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions [Text Block]	On November 13, 2012, we and our subsidiary, CBH, sold our 51% ownership interest in Erye to Fullbright and EET (see Note 15). EET was prior to the sale the holder of the minority 49% ownership interest in Erye, and was a party along with our subsidiary CBH to the Joint Venture Agreement which had governed the ownership of the respective interests in Erye. Fullbright is an affiliate of EET. Mr. Shi Mingsheng (a former member of our Board of Directors, and Chairman of the Board of Erye) and Madam Zhang Jian (the General Manager of Erye, and formerly our Vice President of Pharmaceutical Operations) are the principal equity holders of each of EET and Fullbright. Fullbright assigned all its rights and obligations under the Equity Purchase Agreement (except for its obligations in respect of the return of certain NeoStem securities held by it as part of the purchase price, and its obligations in respect of closing deliverables) to Highacheive Holdings Limited, a limited liability company organized under the laws of the British Virgin Islands and an affiliate of Fullbright (“Highacheive”). As a result of the assignment, the Purchasers of our Erye Interest were EET and Highacheive. In December 2013, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A. (see Note 11). Pursuant to the Loan Modifications, Andrew L. Pecora, M.D., Regional Cancer Care Associates LLC (Dr. Pecora’s medical practice), and certain partners in such practice, including Dr. Pecora, have been released as guarantors of the Second Mortgage Loan, and NeoStem has become a guarantor of the Loans pursuant to a Guaranty of Payment delivered by NeoStem to the Lender. Dr. Pecora, currently currently serves as a NeoStem director, NeoStem’s Chief Visionary Officer, PCT’s Chief Medical Officer and Amorcyte’s Chief Scientific Officer.

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

Commitments and Contingencies [Abstract]

Commitments and Contingencies

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies [Text Block]

Commitments and Contingencies

Lease Commitments

The Company leases offices, of which certain have escalation clauses and renewal options, and also leases equipment under certain noncancelable operating leases that expire from time to time through 2018. In January 2014, the Company signed a new lease for a larger space at its current executive offices at 420 Lexington Avenue, New York, NY 10170. The new lease shall extend through 2018. This property is used as the Company's corporate headquarters. In connection with the CSC Acquisition on May 8, 2014, the Company assumed a facility lease in Irvine, California, with a termination at the end of 2017. We recently signed an amendment expanding our office space in Irvine by 4,000 square feet, and extending the term through 2021. In accordance with the amendment, we plan to occupy the additional space by the second quarter of 2015.

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of December 31, 2014 are as follows (in thousands):



Years ended	Operating Leases
2015	$	1,567.9
2016	1,656.9
2017	1,367.3
2018	535.2
2019	492.4
2020 and thereafter	628.1
Total minimum lease payments	$	6,247.8

Expense incurred under operating leases were approximately $1.3 million , $1.1 million , and $1.5 million for the years ended December 31, 2014, 2013, and 2012, respectively.

Contingencies

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Subsequent Events New Facility Lease We recently entered into an assignment agreement, effective February 19, 2015, for general office space located in Basking Ridge, New Jersey. The space is approximately 18,467 rentable square feet. Pursuant to the agreement, we are not obligated to make any payments for the space until January 2016.The base monthly rent during the period ending January 31, 2016 is currently $25,000 and the lease term ends July 31, 2020. In addition, there are two (2) five (5) year renewal options. In connection with the assumption of the lease, the third party (a) conveyed its rights in various scheduled furniture and equipment and (b) paid the Company approximately $580,000 which amount will offset the rental payments to be paid by NeoStem. A security deposit of approximately $115,000 payable by NeoStem will offset the amount payable by the third party. Common Stock Issuances Pursuant to the Purchase Agreement with Aspire (see Note 12), from January 1, 2015 through March 1, 2015, Aspire has purchased 1.2 million shares of the Company's common stock for an aggregate consideration of approximately $4.4 million.

Available-for-Sale-Securities (Notes)

12 Months Ended

Dec. 31, 2014

Cash, Cash Equivalents, and Marketable Securities [Text Block]

Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	December 31, 2014
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Certificate of deposits	$	249.0	$	—	$	—	$	249.0
Money market funds	12,791.9		—		—		12,791.9
Municipal debt securities	9,317.3		1.3		—		9,318.6
Total	$	22,358.2	$	1.3	$	—	$	22,359.5



	December 31, 2014
Cash and cash equivalents	$	15,279.4
Marketable securities	7,080.1
Total	$	22,359.5

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	December 31, 2014
	Amortized Cost		Estimated Fair Value
Less than one year	$	22,358.2	$	22,359.5
Greater than one year	—		—
Total	$	22,358.2	$	22,359.5

Quarterly Financial Data (Notes)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information [Text Block]

Quarterly Financial Data (unaudited)

The tables below summarize the Company's unaudited quarterly operating results for the years ended December 31, 2014 and 2013, respectively.



	Three Months Ended
(in thousands, except per share data)	March 31, 2014			June 30, 2014			September 30, 2014			December 31, 2014
Revenues	$	4,056		$	4,489		$	4,118		$	5,276
Total operating costs and expenses	$	17,555		$	16,919		$	20,376		$	20,830
Net loss from continuing operations	$	(13,830	)	$	(12,769	)	$	(17,177	)	$	(11,691	)
Net loss attributable to NeoStem, Inc. common stockholders	$	(13,682	)	$	(12,605	)	$	(16,974	)	$	(11,612	)
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders	$	(0.49	)	$	(0.40	)	$	(0.48	)	$	(0.32	)



	Three Months Ended
(in thousands, except per share data)	March 31, 2013			June 30, 2013			September 30, 2013			December 31, 2013
Revenues	$	2,524		$	4,359		$	3,707		$	4,078
Total operating costs and expenses	$	11,355		$	12,530		$	13,020		$	14,573
Net loss from continuing operations	$	(8,864	)	$	(8,626	)	$	(9,277	)	$	(12,719	)
Net loss attributable to NeoStem, Inc. common stockholders	$	(8,801	)	$	(8,575	)	$	(9,071	)	$	(12,535	)
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders	$	(0.53	)	$	(0.46	)	$	(0.45	)	$	(0.47	)

The Business (Tables)

12 Months Ended

Dec. 31, 2014

The Business [Abstract]

Subsidiary [Table Text Block]

These former segments are reported in discontinued operations.



Entity	Percentage of Ownership	Location
NeoStem, Inc.	100%	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
NeoStem Family Storage, LLC	100%	United States of America
Athelos Corporation (1)	96.2%	United States of America
PCT Allendale, LLC	100%	United States of America
NeoStem Oncology, LLC (2)	100%	United States of America

Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Property, Plant and Equipment [Table Text Block]



Building and improvements	25-30 years
Machinery and equipment	8-12 years
Lab equipment	5-7 years
Furniture and fixtures	5-12 years
Software	3-5 years
Leasehold improvements	Life of lease

Property, plant, and equipment consisted of the following (in thousands):



	December 31,
	2014			2013
Building and improvements	$	11,298.7		$	11,229.9
Machinery and equipment	68.3			58.2
Lab equipment	6,324.7			2,743.7
Furniture and fixtures	1,166.3			958.0
Software	312.4			203.1
Leasehold improvements	2,219.6			674.1
Property, plant and equipment, gross	21,390.0			15,867.0
Accumulated depreciation	(5,429.3		)	(3,022.8		)
Property, plant and equipment, net	$	15,960.7		$	12,844.2

Revenue Recognition, Policy [Policy Text Block]

Treasury Stock

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.

We recognize revenues when all of the following conditions are met:


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collectability is probable.

Property, Plant and Equipment, Policy [Policy Text Block]



Building and improvements	25-30 years
Machinery and equipment	8-12 years
Lab equipment	5-7 years
Furniture and fixtures	5-12 years
Software	3-5 years
Leasehold improvements	Life of lease

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

Identified Assets Acquired [Abstract]

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2014

Business Acquisition, Pro Forma Information [Table Text Block]



	Twelve Months Ended December 31, 2014						Twelve Months Ended December 31, 2013
	(As Reported)			(Proforma -Unaudited)			(As Reported)			(Proforma -Unaudited)
Revenues	$	17,939		$	18,649		$	14,668		$	15,471
Net loss	$	(55,467	)	$	(57,964	)	$	(39,485	)	$	(44,790	)
Net loss attributable to NeoStem	$	(54,873	)	$	(57,371	)	$	(38,981	)	$	(44,286	)
Net loss per share attributable to NeoStem	$	(1.68	)	$	(1.51	)	$	(1.90	)	$	(1.71	)

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands):



Cash and cash equivalents	$	51
Accounts receivable trade, net	45
Prepaids and other current assets	19
Property, plant and equipment, net	1,041
Other assets	201
Goodwill	14,092
In-Process R&D	34,290
Accounts payable	(333		)
Accrued liabilities	(2,014		)
Deferred tax liability	(13,901		)
	$	33,491

Availabe-for-Sale-Securities schedule of available-for-Sales (Tables)

12 Months Ended

Dec. 31, 2014

Schedule of Available-for-sale Securities Reconciliation [Table Text Block]

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	December 31, 2014
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Certificate of deposits	$	249.0	$	—	$	—	$	249.0
Money market funds	12,791.9		—		—		12,791.9
Municipal debt securities	9,317.3		1.3		—		9,318.6
Total	$	22,358.2	$	1.3	$	—	$	22,359.5

Marketable Securities [Table Text Block]



	December 31, 2014
Cash and cash equivalents	$	15,279.4
Marketable securities	7,080.1
Total	$	22,359.5

Investments Classified by Contractual Maturity Date [Table Text Block]

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	December 31, 2014
	Amortized Cost		Estimated Fair Value
Less than one year	$	22,358.2	$	22,359.5
Greater than one year	—		—
Total	$	22,358.2	$	22,359.5

Property, Plant & Equipment (Tables)

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]



Building and improvements	25-30 years
Machinery and equipment	8-12 years
Lab equipment	5-7 years
Furniture and fixtures	5-12 years
Software	3-5 years
Leasehold improvements	Life of lease

Property, plant, and equipment consisted of the following (in thousands):



	December 31,
	2014			2013
Building and improvements	$	11,298.7		$	11,229.9
Machinery and equipment	68.3			58.2
Lab equipment	6,324.7			2,743.7
Furniture and fixtures	1,166.3			958.0
Software	312.4			203.1
Leasehold improvements	2,219.6			674.1
Property, plant and equipment, gross	21,390.0			15,867.0
Accumulated depreciation	(5,429.3		)	(3,022.8		)
Property, plant and equipment, net	$	15,960.7		$	12,844.2

Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2014

Loss Per Share [Abstract]

Loss Per Share [Text Block]

Loss Per Share



	December 31,
	2014	2013	2012
Stock Options	4,427,276	2,932,191	2,168,668
Warrants	3,550,956	4,898,266	5,528,761
Restricted Shares	280,481	78,500	34,250

ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]

At December 31, 2014, 2013, and 2012 the Company excluded the following potentially dilutive securities:



	December 31,
	2014	2013	2012
Stock Options	4,427,276	2,932,191	2,168,668
Warrants	3,550,956	4,898,266	5,528,761
Restricted Shares	280,481	78,500	34,250

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2014

Fair Value Measurements [Abstract]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block]



	December 31, 2014								December 31, 2013
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	7,080.0	$	—	$	7,080.0	$	—	$	—	$	—	$	—
	$	—	$	7,080.0	$	—	$	7,080.0	$	—	$	—	$	—	$	—

Liabilities:
Warrant derivative liabilities	—		—		—		—		—		—		23.2		23.2
Contingent consideration	—		—		18,260.0		18,260.0		—		—		9,450.0		9,450.0
	$	—	$	—	$	18,260.0	$	18,260.0	$	—	$	—	$	9,473.2	$	9,473.2

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the year ended December 31, 2014 by type of instrument (in thousands):



	Year Ended
	December 31, 2014
	Warrants			Contingent Consideration			Total
Beginning liability balance	$	23.2		$	9,450.0		$	9,473.2

Amount issued in acquisition	—			11,890.0			11,890.0
Change in fair value recorded in operations	—			(3,080.0		)	(3,080.0		)
Expiration	(23.2		)	—			(23.2		)

Ending liability balance	$	—		$	18,260.0		$	18,260.0

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2014

Goodwill and Other Intangible Assets [Abstract]

Schedule of Goodwill [Table Text Block]

thousands):



	Total
Balance as of December 31, 2013	$	11,117.8
Goodwill resulting from the acquisition of CSC	14,091.5
Balance as of December 31, 2014	$	25,209.3

Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]

s of December 31, 2014 and December 31, 2013 consisted of the following (in thousands):



		December 31, 2014							December 31, 2013
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(395.1	)	$	604.9	$	1,000.0	$	(295.1	)	$	704.9
Manufacturing technology	10 years	3,900.0		(1,540.9		)	2,359.1		3,900.0		(1,150.9		)	2,749.1
Tradename	10 years	800.0		(316.1		)	483.9		800.0		(236.1		)	563.9
In process R&D	Indefinite	43,690.0		—			43,690.0		9,400.0		—			9,400.0
Patent rights	19 years	669.0		(246.5		)	422.5		669.0		(211.3		)	457.7
Total Intangible Assets		$	50,059.0	$	(2,498.6	)	$	47,560.4	$	15,769.0	$	(1,893.4	)	$	13,875.6

Schedule of Amortization Expense [Table Text Block]

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Year Ended December 31,
	2014		2013		2012
Cost of revenue	$	316.8	$	390.0	$	390.0
Research and development	108.4		35.2		35.2
Selling, general and administrative	180.0		180.0		180.0
Total	$	605.2	$	605.2	$	605.2

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):



2015	$	605.2
2016	605.2
2017	605.2
2018	605.2
2019	605.2
Thereafter	44,534.4
	$	47,560.4

Accrued Liabilities Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2014

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities were as follow (in thousands):



	December 31,
	2014		2013
Salaries, employee benefits and related taxes	$	2,807.2	$	2,325.8
Professional fees	495.4		544.8
License fees	—		500.0
Other	1,020.3		647.4
	$	4,322.9	$	4,018.0

Debt Long term debt, maturities (Tables)

12 Months Ended

Dec. 31, 2014

Long-term Debt Disclosure [Abstract]

Schedule of Maturities of Long-term Debt [Table Text Block]



Years Ending December 31,	(in millions)
2015	$	2.4
2016	5.7
2017	5.7
2018	5.4
Total	$	19.2

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2014

Shareholders’ Equity [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The number of remaining shares authorized to be issued under the various equity plans are as follows:



	2003 Equity Plan		2009 Equity Plan
Shares Authorized for Issuance	250,000		8,995,000
Outstanding Stock Options	(122,395	)	(4,304,881	)
Exercised Stock Options	(9,250	)	(80,856	)
Restricted stock or equity grants issued under Equity Plans	(88,993	)	(946,711	)
Shares Expired	(29,362	)	—
Total common shares remaining to be issued under the Equity Plans	—		3,662,552

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the activity for stock options and warrants for the years ended December 31, 2014 and December 31, 2013:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2013	2,932,191		$	11.19	6.81 years	$	1,658.1	4,898,266		$	16.50	2.63	$	1,811.0

Changes during the Year:
Granted	2,265,850		$	6.72				2,722		$	12.26
Exercised	(48,987	)	$	5.53				(333,250	)	$	5.16
Forfeited	(368,704	)	$	6.78				(100,108	)	$	70.00
Expired	(353,116	)	$	12.94				(916,674	)	$	23.95
Outstanding at December 31, 2014	4,427,234		$	9.19	6.93	$	28.6	3,550,956		$	14.12	2.12	$	1.0
Vested at December 31, 2014 or expected to vest in the future	4,253,465		$	9.28	6.84	$	27.0	3,550,956		$	14.12	2.12	$	1.0
Exercisable at December 31, 2014	2,968,379		$	10.22	6.11	$	16.6	3,543,456		$	14.13	2.12	$	1.0

The following table summarizes the components of share-based compensation expense for the years ended December 31, 2014 and 2013 ($ in thousands):



	Year Ended December 31,
	2014		2013		2012
Cost of revenues	$	494.2	$	314.0	$	195.0
Research and development	2,058.2		822.2		432.9
Selling, general and administrative	8,657.1		5,702.5		6,084.6
Total share-based compensation expense	$	11,209.5	$	6,838.7	$	6,712.5

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

During the years ended December 31, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data):



	Year Ended December 31,
	2014		2013
Number of Common Stock Purchase Warrants Issued	—		40,407
Value of Common Stock Purchase Warrants Issued	$	—	$	149.9

Restricted Stock [Table Text Block]

During the years ended December 31, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data):




	2014		2013
Number of Restricted Stock Issued	917,907		514,700
Value of Restricted Stock Issued	$	4,996.3	$	3,360.0

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2014

Share-based Compensation [Abstract]

The following table summarizes the activity for stock options and warrants for the years ended December 31, 2014 and December 31, 2013:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2013	2,932,191		$	11.19	6.81 years	$	1,658.1	4,898,266		$	16.50	2.63	$	1,811.0

Changes during the Year:
Granted	2,265,850		$	6.72				2,722		$	12.26
Exercised	(48,987	)	$	5.53				(333,250	)	$	5.16
Forfeited	(368,704	)	$	6.78				(100,108	)	$	70.00
Expired	(353,116	)	$	12.94				(916,674	)	$	23.95
Outstanding at December 31, 2014	4,427,234		$	9.19	6.93	$	28.6	3,550,956		$	14.12	2.12	$	1.0
Vested at December 31, 2014 or expected to vest in the future	4,253,465		$	9.28	6.84	$	27.0	3,550,956		$	14.12	2.12	$	1.0
Exercisable at December 31, 2014	2,968,379		$	10.22	6.11	$	16.6	3,543,456		$	14.13	2.12	$	1.0

The following table summarizes the components of share-based compensation expense for the years ended December 31, 2014 and 2013 ($ in thousands):



	Year Ended December 31,
	2014		2013		2012
Cost of revenues	$	494.2	$	314.0	$	195.0
Research and development	2,058.2		822.2		432.9
Selling, general and administrative	8,657.1		5,702.5		6,084.6
Total share-based compensation expense	$	11,209.5	$	6,838.7	$	6,712.5

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	4,598.4	$	7.2	$	528.6
Expected weighted-average period in years of compensation cost to be recognized	3.79		0.54		0.31

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

Total fair value of shares vested and the weighted average estimated fair values of shares grant for the year ended December 31, 2014, 2013, and 2012 were as follows ($ in thousands):



	Stock Options						Warrants
	Year Ended December 31,						Year Ended December 31,
	2014		2013		2012		2014		2013		2012
Total fair value of shares vested	$	5,387.1	$	3,375.7	$	5,408.0	$	9.6	$	129.0	$	171.6
Weighted average estimated fair value of shares granted	4.56		4.29		3.63		—		3.71		4.10

Schedule of Range of Fair Value of Stock Options and Warrants [Table Text Block]

The range of assumptions made in calculating the fair values of stock options and warrants was as follow:



	Stock Options						Warrants
	Year Ended December 31,						Year Ended December 31,
	2014		2013		2012		2014		2013		2012
Expected term - minimum (in years)	0		1		2		3		2		2
Expected term - maximum (in years)	10		10		10		3		5		5
Expected volatility - minimum	62%		61%		73%		66%		73%		76%
Expected volatility - maximum	77%		79%		84%		66%		79%		83%
Weighted Average volatility	74	%	72	%	83	%	66	%	74	%	82	%
Expected dividend yield	—		—		—		—		—		—
Risk-free interest rate - minimum	0.12%		0.13%		0.28%		0.79%		0.32%		0.27%
Risk-free interest rate - maximum	3.00%		2.67%		1.99%		0.79%		1.73%		0.88%

Income Taxes income taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Taxes [Abstract]

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]



	Years Ended December 31,
	2014			2013			2012
U.S. Federal benefit at statutory rate	$	(18,894.0	)	$	(13,159.8	)	$	(12,334.1	)
State and local benefit net of U.S. federal tax	(3,435.0		)	(3,430.9		)	(2,154.1		)
Permanent non deductible expenses for U.S. taxes	1,094.6			1,798.2			(2,781.4		)
True-up of prior year net operating loss	(25.5		)	(91.4		)	321.6
Return to actual	—			(3,822.9		)	(384.8		)
Foreign earnings not permanently reinvested	—			—			(1,810.3		)
Effect of change in deferred tax rate	1,075.7			(1,094.8		)	525.7
Valuation allowance for deferred tax assets	20,080.0			20,581.7			18,441.9
Tax provision	$	(104.2	)	$	780.1		$	(175.5	)

Deferred income taxes at December 31, 2014, 2013 and 2012 consist of the following ($ in thousands):

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]



	Years Ended December 31,
	2014			2013			2012
United States	$	(55,570.4	)	$	(38,705.2	)	$	(36,276.9	)
	$	(55,570.4	)	$	(38,705.2	)	$	(36,276.9	)

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]



		Years Ended December 31,
		2014			2013		2012
Current
	US Federal	$	—		$	—	$	—
	State and local	—			—		—
		$	—		$	—	$	—
Deferred
	US Federal	$	159.0		$	476.9	$	—
	State and local	(263.2		)	303.2		(175.5		)
		$	(104.2	)	$	780.1	$	(175.5	)
Total
	US Federal	$	159.0		$	476.9	$	—
	State and local	(263.2		)	303.2		(175.5		)
		$	(104.2	)	$	780.1	$	(175.5	)

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]



	December 31,
	2014			2013			2012
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$	69,047.0		$	43,334.8		$	25,727.7
Deferred revenue	—			10.5			23.1
Contingent accounts payable	(7.8		)	13.6			15.2
Share-based compensation	9,577.2			7,971.9			5,466.7
Intangibles	715.1			704.6			287.3
Accumulated depreciation	—			—			348.7
Charitable contributions	409.8			414.9			391.8
Bad debt provision	296.9			304.3			239.7
Capital loss carry-forward	6,925.1			7,036.8			6,644.5
Other	609.7			—			—
Deferred tax assets prior to tax credit carryovers	87,573.0			59,791.4			39,144.7

Deferred Tax Liabilities:
Accumulated depreciation	$	(18.8	)	$	(64.8	)	$	—
Intangible and indefinite lived assets	(18,176.3		)	(4,379.2		)	(3,599.1		)
Deferred tax liabilities	(18,195.1		)	(4,444.0		)	(3,599.1		)
	69,377.9			55,347.4			35,545.6
Valuation reserve	(87,554.1		)	(59,726.6		)	(39,144.7		)
Net deferred tax liability	$	(18,176.2	)	$	(4,379.2	)	$	(3,599.1	)

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2014

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]

Stock in our balance sheet. The fair values of the canceled options and warrants were based on the Black-Scholes values on the date of sale, and were recorded against Additional Paid in Capital in the accompanying balance sheet. The Company recognized the following loss on the date of sale of its 51% interest in Erye (in thousands):



Fair value of consideration received	$	13,397.9
Carrying value of segment non-controlling interest	6,015.0
Carrying value of segment accumulated comprehensive income	4,387.4
	$	23,800.3
Less carrying amount of assets and liabilities sold:
Cash	$	8,457.5
Restricted Cash	2,918.1
Accounts Receivable	6,130.2
Inventories	15,077.7
Prepaid expenses and other current assets	957.8
Property, plant and equipment, net	38,102.0
Other assets	5,946.3
Accounts payable	(9,604.8		)
Accrued liabilities	(2,008.8		)
Bank loans	(15,133.5		)
Notes payable	(6,599.3		)
Other liabilities	(9,166.8		)
Amount due related party	(7,859.7		)
	$	27,216.7

Loss on exit of segment	$	(3,416.4	)

Regenerative Medicine - China segment [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]

As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):



Cash	$	195.1
Prepaid expenses and other current assets	14.9
Property, plant and equipment, net	1,023.7
Other Assets	330.5
Accounts payable	(177.1		)
Accrued liabilities	(79.2		)
Accumulated comprehensive income	(169.9		)
Loss on exit of segment	$	1,138.0



	Year Ended December 31,
	2012
Revenue	$	52.3
Cost of revenues	(30.6		)
Research and development	(103.3		)
Selling, general, and administrative	(497.3		)
Other income (expense)	(6.8		)
Loss on exit of segment	(1,138.0		)
Loss from discontinued operations	$	(1,723.7	)

Pharmaceutical Manufacturing - China business [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]



	Year Ended December 31,
	2012
Revenue	$	61,703.1
Cost of revenues	(40,245.2		)
Research and development	(1,836.4		)
Selling, general, and administrative	(10,740.0		)
Other expense	(1,045.2		)
Provision for income taxes	(1,794.1		)
Asset impairments	(31,170.1		)
Loss on sale of segment	(3,416.4		)
Loss from discontinued operations	$	(28,544.3	)

Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations Fair value of discontinued operations (Tables)

12 Months Ended

Dec. 31, 2014

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]



Fair value of consideration received	$	13,397.9
Carrying value of segment non-controlling interest	6,015.0
Carrying value of segment accumulated comprehensive income	4,387.4
	$	23,800.3
Less carrying amount of assets and liabilities sold:
Cash	$	8,457.5
Restricted Cash	2,918.1
Accounts Receivable	6,130.2
Inventories	15,077.7
Prepaid expenses and other current assets	957.8
Property, plant and equipment, net	38,102.0
Other assets	5,946.3
Accounts payable	(9,604.8		)
Accrued liabilities	(2,008.8		)
Bank loans	(15,133.5		)
Notes payable	(6,599.3		)
Other liabilities	(9,166.8		)
Amount due related party	(7,859.7		)
	$	27,216.7

Loss on exit of segment	$	(3,416.4	)

Commitments and Contingencies [Abstract]

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2014

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of December 31, 2014 are as follows (in thousands):



Years ended	Operating Leases
2015	$	1,567.9
2016	1,656.9
2017	1,367.3
2018	535.2
2019	492.4
2020 and thereafter	628.1
Total minimum lease payments	$	6,247.8

Equity Plan (Tables)

12 Months Ended

Dec. 31, 2014

Statement of Stockholders' Equity [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The number of remaining shares authorized to be issued under the various equity plans are as follows:



	2003 Equity Plan		2009 Equity Plan
Shares Authorized for Issuance	250,000		8,995,000
Outstanding Stock Options	(122,395	)	(4,304,881	)
Exercised Stock Options	(9,250	)	(80,856	)
Restricted stock or equity grants issued under Equity Plans	(88,993	)	(946,711	)
Shares Expired	(29,362	)	—
Total common shares remaining to be issued under the Equity Plans	—		3,662,552

Available-for-Sale-Securities (Tables)

12 Months Ended

Dec. 31, 2014

Schedule of Available-for-sale Securities Reconciliation [Table Text Block]

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	December 31, 2014
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Certificate of deposits	$	249.0	$	—	$	—	$	249.0
Money market funds	12,791.9		—		—		12,791.9
Municipal debt securities	9,317.3		1.3		—		9,318.6
Total	$	22,358.2	$	1.3	$	—	$	22,359.5

Marketable Securities [Table Text Block]



	December 31, 2014
Cash and cash equivalents	$	15,279.4
Marketable securities	7,080.1
Total	$	22,359.5

Quarterly Financial Data (Tables)

12 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information [Table Text Block]

respectively.



	Three Months Ended
(in thousands, except per share data)	March 31, 2014			June 30, 2014			September 30, 2014			December 31, 2014
Revenues	$	4,056		$	4,489		$	4,118		$	5,276
Total operating costs and expenses	$	17,555		$	16,919		$	20,376		$	20,830
Net loss from continuing operations	$	(13,830	)	$	(12,769	)	$	(17,177	)	$	(11,691	)
Net loss attributable to NeoStem, Inc. common stockholders	$	(13,682	)	$	(12,605	)	$	(16,974	)	$	(11,612	)
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders	$	(0.49	)	$	(0.40	)	$	(0.48	)	$	(0.32	)



	Three Months Ended
(in thousands, except per share data)	March 31, 2013			June 30, 2013			September 30, 2013			December 31, 2013
Revenues	$	2,524		$	4,359		$	3,707		$	4,078
Total operating costs and expenses	$	11,355		$	12,530		$	13,020		$	14,573
Net loss from continuing operations	$	(8,864	)	$	(8,626	)	$	(9,277	)	$	(12,719	)
Net loss attributable to NeoStem, Inc. common stockholders	$	(8,801	)	$	(8,575	)	$	(9,071	)	$	(12,535	)
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders	$	(0.53	)	$	(0.46	)	$	(0.45	)	$	(0.47	)

The Business (Details) - USD ($)	12 Months Ended
The Business (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Subsidiary or Equity Method Investee [Line Items]
Change in Ownership in Subsidiary	$ 0	$ 0
NeoStem, Inc. [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Location [Member] \| NeoStem, Inc. [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| NeoStem Therapies, Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| Stem Cell Technologies, Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| Amorcyte, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| Progenitor Cell Therapy, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| NeoStem Family Storage, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| Athelos Corporation [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
Location [Member] \| PCT Allendale, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Entity Location	United States of America
UNITED STATES \| NeoStem Therapies, Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
UNITED STATES \| Stem Cell Technologies, Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
UNITED STATES \| Amorcyte, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
UNITED STATES \| Progenitor Cell Therapy, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
UNITED STATES \| NeoStem Family Storage, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
UNITED STATES \| Athelos Corporation [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	96.20%
UNITED STATES \| PCT Allendale, LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
UNITED STATES \| NeoStem Oncology [Member]
Subsidiary or Equity Method Investee [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Entity Location	United States of America
Noncontrolling Interest [Member]
Subsidiary or Equity Method Investee [Line Items]
Change in Ownership in Subsidiary	$ 700,000

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Concentration Risk, Percentage	0.00%
Issuance Of Common Stock In Connection With Preferred Stock Settlement Value			$ 674,194
Clinical Services Reimbursement	$ 3,700,000	$ 2,100,000	$ 3,500,000
Revene Recognition Period for Cryoperservation Process	24 hours
Building and Building Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P25Y
Building and Building Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P30Y
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P8Y
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P12Y
Lab Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P5Y
Lab Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P7Y
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P5Y
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P12Y
Computer Software, Intangible Asset [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P3Y
Computer Software, Intangible Asset [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P5Y
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	life of lease
NeoStem, Inc. [Member]
Property, Plant and Equipment [Line Items]
Concentration Risk, Percentage	0.00%

Acquisitions Fair value of assets acquired and liabilities (Details) - USD ($)	3 Months Ended								8 Months Ended	12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	May 08, 2014
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents													$ 51,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment													1,041,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other													201,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent													$ 13,901,000
Common Stock, Shares, Issued													5,329,593
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High													$ 90,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net													19,400,000
Business Acquisition, Transaction Costs													33,500,000
Goodwill	$ 25,209,336				$ 11,117,770				$ 25,209,336	$ 25,209,336	$ 11,117,770		14,092,000
Equity Issued in Business Combination, Fair Value Disclosure													21,600,000
Business Combination, Contingent Consideration, Liability	$ 18,260,000				$ 9,450,000				18,260,000	$ 18,260,000	$ 9,450,000		11,900,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual									40,000
Business Acquisition, Pro Forma Net Income (Loss)									$ (7,600,000)
NeoStem, Inc. common stockholders	$ (0.32)	$ (0.48)	$ (0.40)	$ (0.49)	$ (0.47)	$ (0.45)	$ (0.46)	$ (0.53)		$ (1.68)	$ (1.90)	$ (4.00)
Business Combination, Acquired Receivables, Fair Value													45,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets													19,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill													34,290,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable													333,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities													2,014,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net													$ 33,491,000

Acquisitions CSC acquisitions (Details) - USD ($)	3 Months Ended								8 Months Ended	12 Months Ended
Acquisitions CSC acquisitions (Details) - USD ($)	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	May 08, 2014
Business Acquisition [Line Items]
Revenues	$ 5,276	$ 4,118	$ 4,489	$ 4,056	$ 4,078	$ 3,707	$ 4,359	$ 2,524		$ 17,938,790	$ 14,668,455	$ 14,329,889
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual									$ 40,000
Common Stock, Shares, Issued													5,329,593
Business Acquisition, Transaction Costs													$ 33,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents													51,000
Business Combination, Acquired Receivables, Fair Value													45,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets													19,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment													1,041,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other													201,000
Goodwill	25,209,336				11,117,770				25,209,336	25,209,336	11,117,770		14,092,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill													34,290,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable													333,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities													2,014,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent													13,901,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net													33,491,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High													90,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net													19,400,000
Equity Issued in Business Combination, Fair Value Disclosure													21,600,000
Business Combination, Contingent Consideration, Liability	$ 18,260,000				$ 9,450,000				18,260,000	$ 18,260,000	$ 9,450,000		$ 11,900,000
Business Acquisition, Pro Forma Net Income (Loss)									$ (7,600,000)
NeoStem, Inc. common stockholders	$ (0.32)	$ (0.48)	$ (0.40)	$ (0.49)	$ (0.47)	$ (0.45)	$ (0.46)	$ (0.53)		$ (1.68)	$ (1.90)	$ (4.00)
Net loss										$ (55,466,246)	$ (39,485,334)	$ (66,369,311)
Net Income (Loss) Attributable to Parent	$ (11,612)	$ (16,974)	$ (12,605)	$ (13,682)	$ (12,535)	$ (9,071)	$ (8,575)	$ (8,801)		(54,872,933)	(38,981,244)	$ (53,769,484)
NeoStem, Inc. [Member]
Business Acquisition [Line Items]
Revenues										$ 17,939,000	$ 14,668,000
NeoStem, Inc. common stockholders										$ (1.68)	$ (1.90)
Net loss										$ (55,467,000)	$ (39,485,000)
Net Income (Loss) Attributable to Parent										(54,873,000)	(38,981,000)
NeoStem Oncology [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue										18,649,000	15,471,000
Business Acquisition, Pro Forma Net Income (Loss)										(57,964,000)	(44,790,000)
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual										$ (57,371,000)	$ (44,286,000)
Business Acquisition, Pro Forma Earnings Per Share, Diluted										$ (1.51)	$ (1.71)

Availabe-for-Sale-Securities Available-for-Sale-Securities (Details) - USD ($)	Dec. 31, 2014	Sep. 30, 2014
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	$ 22,358,200
Gross Unrealized Gains	1,300
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0
Fair Value, Estimate Not Practicable, Investments	22,359,500
Cash and cash equivalents	15,279,400
Available-for-sale Securities, Current	7,080,100
Cash, Cash Equivalents, and Short-term Investments	22,359,500
Available-for-sale Securities, Debt Maturities, Next Rolling Twelve Months, Amortized Cost Basis	22,358,200	$ 22,358,200
Available-for-sale Securities, Debt Maturities, Next Rolling Twelve Months, Fair Value	22,359,500
Available-for-sale Securities, Debt Securities	22,359,500
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	9,317,300
Gross Unrealized Gains	1,300
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0
Fair Value, Estimate Not Practicable, Investments	9,318,600
Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	12,791,900
Gross Unrealized Gains	0
Money Market Funds, at Carrying Value	12,791,900
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	249,000
Gross Unrealized Gains	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0
Fair Value, Estimate Not Practicable, Investments	$ 249,000

Deferred Costs (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Schedule of Inventory [Line Items]
Deferred Costs	$ 2,566,989	$ 1,270,223
Multiple Stage Contracts [Member]
Schedule of Inventory [Line Items]
Deferred Revenue	$ 3,900,000	$ 1,500,000

Property, Plant & Equipment (Details) - USD ($)	12 Months Ended
Property, Plant & Equipment (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Buildings and Improvements, Gross	$ 11,298,700	$ 11,229,900
Depreciation, Depletion and Amortization	1,600,000	1,000,000	$ 1,000,000
Property, plant and equipment, net	15,960,731	12,844,216
Machinery and Equipment, Gross	68,300	58,200
Property, Plant and Equipment, Other, Gross	6,324,700	2,743,700
Furniture and Fixtures, Gross	1,166,300	958,000
Capitalized Computer Software, Gross	312,400	203,100
Leasehold Improvements, Gross	2,219,600	674,100
Property, Plant and Equipment, Gross	21,390,000	15,867,000
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(5,429,300)	(3,022,800)
Property, Plant and Equipment, Other Types [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 15,960,700	$ 12,844,200

Loss Per Share (Details) - shares	12 Months Ended
Loss Per Share (Details) - shares	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Options [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	4,427,276	2,932,191	2,168,668
Warrant [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	3,550,956	4,898,266	5,528,761
Restricted Stock [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	280,481	78,500	34,250

Fair Value Measurements Fair value hierarchy the Company’s financial assets and liabilities (Details) - USD ($)	Dec. 31, 2014	May 08, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 90,000,000
Business Combination, Contingent Consideration, Liability	$ 18,260,000	$ 11,900,000	$ 9,450,000

Fair Value Measurements Financial instruments with significant Level 3 inputs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	May 08, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Warrant Derivative Liabilities	$ 0	$ 23,200
Business Combination, Contingent Consideration, Liability	18,260,000	9,450,000		$ 11,900,000
Fair Value, Net Asset (Liability)	18,260,000	9,473,200
Changes in acquisition-related contingent consideration	11,890,000
Changes in acquisition-related contingent consideration	(3,080,000)	1,900,000	$ 4,420,000
Change in warrant liabilities	(23,200)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances		9,473,200
Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Available-for-sale Securities	7,080,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Warrant Derivative Liabilities		23,200
Business Combination, Contingent Consideration, Liability	$ 18,260,000	9,450,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances		$ 9,473,200

Goodwill and Other Intangible Assets Goodwill (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Line Items]
Future Amortization Expense, Year One	$ 605,200
Future Amortization Expense, Year Two	605,200
Future Amortization Expense, Year Three	605,200
Future Amortization Expense, Year Four	605,200
Future Amortization Expense, Year Five	605,200
Future Amortization Expense, after Year Five	44,534,400
Finite-Lived Intangible Assets, Net	$ 47,560,400	$ 13,875,600

Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 50,059,000	$ 15,769,000
Finite-Lived Intangible Assets, Accumulated Amortization	(2,498,600)	(1,893,400)
Finite-Lived Intangible Assets, Net	47,560,400	13,875,600
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,000,000	1,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	(395,100)	(295,100)
Finite-Lived Intangible Assets, Net	$ 604,900	704,900
Finite-Lived Intangible Assets, Useful Life	10 years
Manufacturing Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 3,900,000	3,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	(1,540,900)	(1,150,900)
Finite-Lived Intangible Assets, Net	$ 2,359,100	2,749,100
Finite-Lived Intangible Assets, Useful Life	10 years
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 800,000	800,000
Finite-Lived Intangible Assets, Accumulated Amortization	(316,100)	(236,100)
Finite-Lived Intangible Assets, Net	$ 483,900	563,900
Finite-Lived Intangible Assets, Useful Life	10 years
In Process R&D [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 43,690,000	9,400,000
Finite-Lived Intangible Assets, Accumulated Amortization	0	0
Finite-Lived Intangible Assets, Net	$ 43,690,000	9,400,000
Finite Lived Intangible Assets, Useful Life [String]	Indefinite
VSEL Patent Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 669,000	669,000
Finite-Lived Intangible Assets, Accumulated Amortization	(246,500)	(211,300)
Finite-Lived Intangible Assets, Net	$ 422,500	$ 457,700
Finite-Lived Intangible Assets, Useful Life	19 years

Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	$ 605,200	$ 605,200	$ 605,200
Cost of Sales [Member]
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	316,800	390,000	390,000
General and Administrative Expense [Member]
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	180,000	180,000	180,000
Research and Development Expense [Member]
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	$ 108,400	$ 35,200	$ 35,200

Accrued Liabilities Accrued Liabilities (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities [Abstract]
Employee-related Liabilities	$ 2,807.2	$ 2,325.8
Accrued Professional Fees	495.4	544.8
Accrued Royalties, Current	0.0	500.0
Other Accrued Liabilities	1,020.3	647.4
Accrued Liabilities	$ 4,322.9	$ 4,018.0

Debt (Details) - USD ($)			12 Months Ended
Debt (Details) - USD ($)	Dec. 06, 2010	Oct. 31, 2007	Dec. 31, 2014	Sep. 26, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Debt Instrument, Annual Principal Payment			$ 19,200,000
Interest Expense, Long-term Debt			300,000
Notes Payable			1,600,000		$ 900,000
Secured Long-term Debt, Noncurrent				$ 20,000,000
Debt Instrument, Periodic Payment			10,000,000
Mortgage Loans on Real Estate, Carrying Amount of Mortgages			3,100,000
Proceeds from Issuance of Debt			11,300,000
Debt issuance costs			$ 100,000
Payment Guarantee [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Interest			8.00%
Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum			8.50%
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Purchase of condominium units		$ 3,800,000
Debt Instrument, Periodic Payment, Interest		5.00%
Mortgage Loans on Real Estate, Carrying Amount of Mortgages					2,500,000
Mortgage Loans on Real Estate, New Mortgage Loans		$ 3,100,000
NeoStem, Inc. [Member] \| Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Period of Loan			36 months
Debt Instrument, Term			30 months
PCT Allendale, LLC [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment		$ 20,766
PCT Allendale, LLC [Member] \| Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Period of Loan	124 months
Debt Instrument, Periodic Payment, Interest	6.00%
Debt Instrument, Period of Fixed Interest Rate	64 months
Mortgage Loans on Real Estate, Carrying Amount of Mortgages					$ 763,000
Mortgage Loans on Real Estate, New Mortgage Loans	$ 1,000,000
Long-term Debt [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross				15,000,000
License Agreement Terms [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross				$ 5,000,000
Less than one year [Member]
Debt Instrument [Line Items]
Debt Instrument, Annual Principal Payment			$ 2,400,000
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Debt Instrument, Annual Principal Payment			5,700,000
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument [Line Items]
Debt Instrument, Annual Principal Payment			5,700,000
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument [Line Items]
Debt Instrument, Annual Principal Payment			$ 5,400,000

Preferred Stock Convertible Redeemable Series E Preferred Stock (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Class of Stock [Line Items]
Net proceeds from issuance of capital stock	$ 16,710,645	$ 58,736,165	$ 16,428,827

Shareholders' Equity (Details)	12 Months Ended
Shareholders' Equity (Details)	Dec. 31, 2014 USD ($) $ / shares shares	Dec. 31, 2013 USD ($) $ / shares shares	Dec. 31, 2012 USD ($) shares	Mar. 31, 2014 USD ($)	Oct. 10, 2012 shares	Oct. 14, 2011 shares	Sep. 28, 2011 USD ($)	Jan. 18, 2011 shares	Jun. 02, 2010 shares	Oct. 29, 2009 shares	May 09, 2009 shares
Class of Stock [Line Items]
weighted average estimated fair value of restricted stock \| $ / shares	$ 5.44	$ 6.53
Stock Issued During Period, Shares, Restricted Stock Award, Gross	917,907	514,700
Proceeds from Warrant Exercises \| $	$ 1,720,725	$ 3,028,241	$ 6,604,418
Stock Issued During Period, Value, Warrant Inducements \| $		$ 62,014	$ 228,676
Warrant inducements	0	40,407
Stock Issued During Period, Value, Restricted Stock Award, Gross \| $	$ 4,996,300	$ 3,360,000
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	2,959,214	9,712,724	3,573,229
Stock Issued During Period, Value, Warrant Inducements \| $		$ 0	$ 146
Warrant inducements		0	145,895.2
Warrant holder A [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	333,250
Proceeds from Issuance of Warrants \| $	$ 1,700,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Committment Value Under Purchase Agreement \| $				$ 20,000,000			$ 20,000,000
Term Of Agreement In Months				24			24
Discount Applied To Weighted Average Price				5.00%
Non US Equity Plan [Member] \| Stock Options [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized					570,000
2009 Equity Plan [Member] \| Stock Options [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized	8,995,000	5,995,000			450,000	2,375,000		1,775,000	1,375,000	975,000	380,000

Shareholders' Equity Components of share-based compensation expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 10, 2012	Oct. 14, 2011	Jan. 18, 2011	Jun. 02, 2010	Oct. 29, 2009	May 09, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	(3,543,456)
Share-based Compensation Expense	$ 11,209,500	$ 6,838,700	$ 6,712,500
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	494,200	314,000	195,000
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	2,058,200	822,200	432,900
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	$ 8,657,100	$ 5,702,500	$ 6,084,600
Stock Options [Member] \| 2009 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized	8,995,000	5,995,000		450,000	2,375,000	1,775,000	1,375,000	975,000	380,000
Stock Options [Member] \| Non US Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized				570,000
2009 Equity Plan [Member] \| US Equity Plan [Member] \| Stock Options [Member] \| 2009 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	(80,856)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	(946,711)
Shares Expired	0
Common Stock, Shares Authorized	8,995,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	(4,304,881)
Common Stock, Shares, Outstanding	(3,662,552)
2003 Equity Plan [Member] \| US Equity Plan [Member] \| Stock Options [Member] \| 2003 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	(9,250)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	(88,993)
Shares Expired	(29,362)
Common Stock, Shares Authorized	250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	(122,395)
Common Stock, Shares, Outstanding	0

Shareholders' Equity Activity for stock options and warrants (Details)	12 Months Ended
	Dec. 31, 2014 USD ($) $ / shares $ / warrant shares	Dec. 31, 2013 USD ($) $ / shares $ / warrant shares	Dec. 31, 2012 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value \| $	$ 28,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 16,600	$ 1,658,100
Common Stock Warrants, Shares		4,898,266
Weighted Average Exercise Price, Warrants Outstanding \| $ / warrant	14.12	16.5
Weighted Average Remaining Contractual Term warrant outstanding	2 years 1 month 13 days
Weighted Average Remaining Contractual Term, Warrants Outstanding		2 years 7 months 17 days
Aggregate Intrinsic Value, Warrants Outstanding \| $	$ 1,000	$ 1,811,000
Warrant inducements	0	40,407
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward]
Warrants Granted	2,722
Weighted Average Exercise Price, Warrants Granted \| $ / shares	$ 12.26
Warrants Exercised	(333,250)
Weighted Average Exercise Price, Warrants Exercised \| $ / shares	$ 5.16
Warrants Expired	(100,108)
Weighted Average Exercise Price, Warrants Expired \| $ / shares	$ 70
Warrants Canceled	(916,674)
Weighted Average Exercise Price, Warrants Canceled \| $ / shares	$ 23.95
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value \| $	$ 27,000
shares, vested and expected to vest	3,550,956
Weighted Average Exercise Price, Warrants vested & expected to vest \| $ / warrant	14.12
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	3,543,456
Weighted Average Exercise Price, Warrants Exercisable \| $ / warrant	14.13
weighted Average Remaining Contractual Term, warrants vested	2 years 1 month 13 days
Aggregate Intrinsic Value, Warrants vested and expected to vest \| $	$ 1,000
Aggregate Intrinsic Value, Warrants vested \| $	1,000
Warrants Issued During Period, Value \| $	$ 0	$ 149,900
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price \| $ / shares	$ 0.00	$ 3.71	$ 4.10
US Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 9.19	$ 11.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 11 months 5 days	6 years 9 months 22 days
Common Stock, Shares, Outstanding	3,550,956
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	2 years 1 month 13 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	4,253,465
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 9.28
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	6 years 10 months 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	2,265,850
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	$ 6.72
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward]
Stock Options, Outstanding at December 31, 2011	2,932,191
Stock Options Exercised	(48,987)
Stock Options Forfeited	(353,116)
Stock Options Expired	(368,704)
Stock Options, Outstanding at September 30, 2012	4,427,234	2,932,191
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price \| $ / shares	$ 12.94
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price \| $ / shares	6.78
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	$ 5.53
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	2,968,379
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price \| $ / shares	$ 10.22
Options, Vested, weighted Average Remaining Contractual Term	6 years 1 month 10 days

Shareholders' Equity Total compensation cost related to nonvested awards (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	917,907	514,700
weighted average estimated fair value of restricted stock	$ 5.44	$ 6.53
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 4,996,300	$ 3,360,000
Restricted Stock [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost	$ 528,600
Excepted weighted-average period in years of compensation cost to be recognized	3 months 22 days
Warrant [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost	$ 7,200
Excepted weighted-average period in years of compensation cost to be recognized	6 months 15 days
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost	$ 4,598,400
Excepted weighted-average period in years of compensation cost to be recognized	3 years 9 months 15 days

Shareholders' Equity Equity Issuances (Details)	3 Months Ended	12 Months Ended
Shareholders' Equity Equity Issuances (Details)	Mar. 31, 2014 USD ($) shares	Dec. 31, 2014 USD ($) shares	Dec. 31, 2013 USD ($) shares	Dec. 31, 2012 USD ($)	May 08, 2014 shares	Feb. 28, 2013 shares	Sep. 28, 2011 USD ($)
Class of Stock [Line Items]
Warrant inducements \| shares		0	40,407
Common Stock, Shares, Issued \| shares					5,329,593
Proceeds from issuance of common stock		$ 16,710,645	$ 58,736,166	$ 16,428,827
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Committment Value Under Purchase Agreement	$ 20,000,000						$ 20,000,000
Proceeds from Issuance of Common Stock	$ 5,600,000
Term Of Agreement In Months	24						24
Discount Applied To Weighted Average Price	5.00%
Proceeds from issuance of common stock		10,900,000
Purchase Commitment, Remaining Minimum Amount Committed		$ 19,100,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues \| shares	800,000
Common Stock, Shares, Issued \| shares	150,000					1,600,000
Purchase Commitment, Remaining Minimum Amount Committed	$ 30,000,000

Shareholders' Equity Warrants (Details) - USD ($)	12 Months Ended
Shareholders' Equity Warrants (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price, Warrants Exercised	$ 5.16
Warrants Issued During Period, Value	$ 0	$ 149,900
Warrant inducements	0	40,407
Warrant holder A [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	333,250
Proceeds from Issuance of Warrants	$ 1,700,000

Shareholders' Equity Equity Plan (Details) - USD ($)	12 Months Ended
Shareholders' Equity Equity Plan (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Oct. 10, 2012	Oct. 14, 2011	Jan. 18, 2011	Jun. 02, 2010	Oct. 29, 2009	May 09, 2009
Stock Options [Member] \| 2009 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized	8,995,000	5,995,000	450,000	2,375,000	1,775,000	1,375,000	975,000	380,000
Stock Options [Member] \| Non US Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized			570,000
ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized	500,000
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	15.00%
ESPP annual cap	$ 25,000
percentage of stock closing price	85.00%
percentage of ESPP closing price	85.00%
Shares, Issued	65,441
Shares, Outstanding	434,559

Shareholders' Equity Options (Details) - USD ($)	12 Months Ended
Shareholders' Equity Options (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	48,987
Proceeds from exercise of options	$ 271,008	$ 150,658	$ 0
Maximum [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 6.20
Minimum [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 5.20

Share-Based Compensation (Details)	12 Months Ended
Share-Based Compensation (Details)	Dec. 31, 2014 USD ($)
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 4,598,400
Excepted weighted-average period in years of compensation cost to be recognized	3 years 9 months 15 days
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 7,200
Excepted weighted-average period in years of compensation cost to be recognized	6 months 15 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 528,600
Excepted weighted-average period in years of compensation cost to be recognized	3 months 22 days

Share-Based Compensation Share-Based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 11,209,500	$ 6,838,700	$ 6,712,500
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	494,200	314,000	195,000
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	2,058,200	822,200	432,900
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	8,657,100	5,702,500	6,084,600
Warrant [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition	$ 9,600	$ 129,000	$ 171,600
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	66.00%	73.00%	76.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	66.00%	79.00%	83.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.79%	0.32%	0.27%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	0.79%	1.73%	0.88%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$ 0.00	$ 3.71	$ 4.10
Stock Options [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$ 4.56	$ 4.29	$ 3.63
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition	$ 5,387,100	$ 3,375,700	$ 5,408,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	62.00%	61.00%	73.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	77.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.12%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	3.00%	0.00%	0.00%

Share-Based Compensation Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Option [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	62.00%	61.00%	73.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	77.00%	0.00%	0.00%
Fair Value Assumptions, Weighted Average Volatility Rate	74.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.12%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	3.00%	0.00%	0.00%
Warrant [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	66.00%	73.00%	76.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	66.00%	79.00%	83.00%
Fair Value Assumptions, Weighted Average Volatility Rate	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.79%	0.32%	0.27%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	0.79%	1.73%	0.88%
Minimum [Member] \| Stock Option [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	0 years	1 year	2 years
Minimum [Member] \| Warrant [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	3 years	2 years	2 years
Maximum [Member] \| Stock Option [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	10 years	10 years	10 years
Maximum [Member] \| Warrant [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	3 years	5 years	5 years

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Examination [Line Items]
Current Federal Tax Expense (Benefit)	$ 0	$ 0	$ 0
Deferred State and Local Income Tax Expense (Benefit)	(263,200)	303,200	(175,500)
Federal Income Tax Expense (Benefit), Continuing Operations	159,000	476,900	0
State and Local Income Tax Expense (Benefit), Continuing Operations	(263,200)	303,200	(175,500)
Deferred Federal Income Tax Expense (Benefit)	159,000	476,900	0
Current State and Local Tax Expense (Benefit)	0	0	0
Current Income Tax Expense (Benefit)	$ 0	0	0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	34.00%
Operating Loss Carryforwards	$ 177,200,000	110,600,000
Deferred income taxes	(104,200)	780,100	(175,500)
Income Tax Expense (Benefit)	(104,202)	780,104	(175,533)
Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate	(18,894,000)	(13,159,800)	(12,334,100)
Income Tax Reconciliation, State and Local Income Taxes	(3,435,000)	(3,430,900)	(2,154,100)
Permanent non deductible expenses for U.S. taxes	1,094,600	1,798,200	(2,781,400)
Restatement of Prior Year Income, Net of Tax	(25,500)	(91,400)	321,600
Income Tax Reconciliation, Other Adjustments	0	(3,822,900)	(384,800)
Income Tax Reconciliation, Undistributed Foreign Earnings	0	0	(1,810,300)
Income Tax Reconciliation, Change in Enacted Tax Rate	1,075,700	(1,094,800)	525,700
Deferred Tax Assets, Valuation Allowance	20,080,000	20,581,700	18,441,900
Unrecognized Tax Benefits Resulting in Net Operating Loss Carryforward	69,047,000	43,334,800	25,727,700
Deferred Tax Assets, Deferred Income	0	10,500	23,100
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities	(7,800)	13,600	15,200
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	9,577,200	7,971,900	5,466,700
Deferred Tax Assets, Goodwill and Intangible Assets	715,100	704,600	287,300
Deferred Tax Assets, Other	0	0	(348,700)
Deferred Tax Assets, Charitable Contribution Carryforwards	409,800	414,900	391,800
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts	296,900	304,300	239,700
Deferred Tax Assets, Capital Loss Carryforwards	6,925,100	7,036,800	6,644,500
Deferred Tax Assets, Tax Credit Carryforwards, Other	609,700	0	0
Deferred Tax Assets, Net	87,573,000	59,791,400	39,144,700
Deferred Tax Liabilities Accumulated depreciation	(18,800)	(64,800)	0
Deferred Tax Liabilities, Goodwill and Intangible Assets, Intangible Assets	(18,176,300)	(4,379,200)	(3,599,100)
Deferred Tax Liabilities, Gross	18,195,100	4,444,000	3,599,100
Deferred Tax Assets (Liabilities), Net	69,377,900	55,347,400	3,599,100
Valuation Allowances and Reserves, Balance	(87,554,100)	(59,726,600)	(39,144,700)
Deferred Tax Liabilities	$ (18,176,200)	$ (4,379,200)	$ (35,545,600)

Income Taxes Net Operating Loss Carry Forward (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net Operating Loss Carry Forward [Abstract]
Income Tax Expense (Benefit)	$ (104,202)	$ 780,104	$ (175,533)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	34.00%

Discontinued Operations (Details) - USD ($)	12 Months Ended
Discontinued Operations (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue	$ 52,300
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	30,600
Disposal Group Including Discontinued Operation Research and Development	103,300
Disposal Group Including Discontinued Operation Selling General and Administrative	497,300
Disposal Group, Including Discontinued Operation, Operating Expense	6,800
Loss on Exit of Segment	1,138,000
Pharmaceutical Manufacturing - China business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue	61,703,100
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents		$ 8,457,500
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	40,245,200
Disposal Group Including Discontinued Operation Research and Development	1,836,400
Disposal Group Including Discontinued Operation Selling General and Administrative	10,740,000
Disposal Group, Including Discontinued Operation, Operating Expense	$ 1,045,200

Discontinued Operations Company recognized loss on exit (Details) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment		$ 0	$ 0	$ 30,267,990
Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	$ 1,138,000
Pharmaceutical Manufacturing - China business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment			$ 3,416,400	$ 3,416,400

Discontinued Operations The operating results of the Regenerative Medicine – China business (Details) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	May 08, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					$ 1,041,000
Loss on exit of segment		$ 0	$ 0	$ 30,267,990
Disposal Group, Including Discontinued Operation, Operating Income (Loss)		$ 0	0	$ (17,955,344)
Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	$ 1,138,000
Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue			52,300
Disposal Group, Including Discontinued Operation, Costs of Goods Sold			(30,600)
Disposal Group Including Discontinued Operation Research and Development			(103,300)
Disposal Group Including Discontinued Operation Selling General and Administrative			(497,300)
Disposal Group, Including Discontinued Operation, Operating Expense			(6,800)
Loss on Exit of Segment			1,138,000
Disposal Group, Including Discontinued Operation, Operating Income (Loss)			$ (1,723,700)
Cash and Cash Equivalents [Member] \| Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	195,100
Gain (Loss) on Disposition of Prepaid Expenses and Other Current Assets [Member] \| Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	14,900
Gain (Loss) on Disposition of Other Assets	(330,500)
Gain (Loss) on Disposition of Property, Plant and Equipment, Net [Member] \| Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	1,023,700
Gain (Loss) on Disposition of Accounts Payable [Member] \| Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	(177,100)
Gain (Loss) on Disposition of Accrued Liabilities [Member] \| Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	(79,200)
Gain (Loss) on Disposition of Accumulated Comprehensive Income [Member] \| Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	$ (169,900)

Discontinued Operations The summary of assets and liabilities related to Regenerative Medicine - China business (Details) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment		$ 0	$ 0	$ 30,267,990
Assets:
Assets of Disposal Group, Including Discontinued Operation				$ 23,800,300
Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	$ 1,138,000

Discontinued Operations The operating results of pharmaceutical manufacturing - China business (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	$ 0	$ 0	$ (30,267,990)
Pharmaceutical Manufacturing - China business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue		61,703,100
Disposal Group, Including Discontinued Operation, Costs of Goods Sold		(40,245,200)
Disposal Group Including Discontinued Operation Research and Development		(1,836,400)
Disposal Group Including Discontinued Operation Selling General and Administrative		(10,740,000)
Disposal Group, Including Discontinued Operation, Operating Expense		(1,045,200)
Loss on exit of segment		$ (3,416,400)	$ (3,416,400)

Discontinued Operations The summary of the assets and liabilities related to Pharmaceutical Manufacturing- China discontinued operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 13, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Noncontrolling interests	$ (441,047)	$ (516,040)
Cash and cash equivalents	19,174,061	46,133,759		$ 12,300,000
Total assets			$ 23,800,300
Loss on exit of segment	$ 0	0	(30,267,990)
Treasury Stock, Shares				104,000
Stock Option Cancelled				117,000
Warrants Cancelled				64,000
Pharmaceutical Manufacturing - China business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Available-for-sale Securities			13,397,900
Noncontrolling interests			6,015,000
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax			4,387,400
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents			8,457,500
Restricted cash			2,918,100
Accounts receivable, net			6,130,200
Inventory			15,077,700
Prepaid expenses and other current assets			957,800
Property, plant and equipment, net			38,102,000
Other assets			5,946,300
Total assets			27,216,700
Accounts Payable			(9,604,800)
Accrued liabilities			(2,008,800)
Bank loans			(15,133,500)
Notes payable			(6,599,300)
Unearned revenue			(9,166,800)
Amount due related parties			(7,859,700)
Loss on exit of segment		$ (3,416,400)	$ (3,416,400)

Discontinued Operations Summary of Operations and Cash Flows of the Pharmaceutical Manufacturing China Business (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	$ 0	$ 0	$ (30,267,990)
Pharmaceutical Manufacturing - China business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue		61,703,100
Disposal Group, Including Discontinued Operation, Costs of Goods Sold		(40,245,200)
Disposal Group Including Discontinued Operation Research and Development		(1,836,400)
Disposal Group Including Discontinued Operation Selling General and Administrative		(10,740,000)
Disposal Group, Including Discontinued Operation, Operating Expense		(1,045,200)
Discontinued Operation, Provision for Loss (Gain) on Disposal, before Income Tax		(1,794,100)
Disposal Group Including Discontinued Operation Assets Impairment		(31,170,100)
Loss on exit of segment		(3,416,400)	$ (3,416,400)
Disposal Group, Including Discontinued Operation, Operating Income (Loss)		$ (28,544,300)

Related Party Transactions (Details) - Equity Purchase Agreement [Member]	Dec. 31, 2012	Jun. 18, 2012
CBH Acquisition LLC [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage	51.00%
EET and Fullbright [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent		49.00%

Commitments and Contingencies (Details) - USD ($)	12 Months Ended
Commitments and Contingencies (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Commitments and Contingencies [Abstract]
Operating Leases, Future Minimum Payments, Next Rolling Twelve Months	$ 1,567,900
Operating Leases, Future Minimum Payments Due [Abstract]
2013	1,656,900
2014	1,367,300
2015	535,200
2016	492,400
Thereafter	628,100
Total minimum lease payments	6,247,800
Operating Leases, Rent Expense	$ 1,300,000	$ 1,100,000	$ 1,500,000

Subsequent Events (Details) - USD ($)	3 Months Ended	12 Months Ended
Subsequent Events (Details) - USD ($)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	May 08, 2014	Mar. 31, 2014	Feb. 28, 2013
Subsequent Event [Line Items]
Common Stock, Shares, Issued					5,329,593
Proceeds from issuance of common stock		$ 16,710,645	$ 58,736,166	$ 16,428,827
Proceeds from exercise of warrants		$ 1,720,725	3,028,241	6,604,418
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number		3,543,456
Proceeds from exercise of options		$ 271,008	$ 150,658	$ 0
Lease Agreements [Member]
Subsequent Event [Line Items]
Deferred Rent Credit	$ 580,000
Security Deposit	$ 115,000
Aspire Capital Purchase Agreement [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued						150,000	1,600,000
Aspire Capital Purchase Agreement [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued	1,200,000
Proceeds from issuance of common stock	$ 4,400,000

Quarterly Financial Data (Details) - USD ($)	3 Months Ended								12 Months Ended
Quarterly Financial Data (Details) - USD ($)	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 5,276	$ 4,118	$ 4,489	$ 4,056	$ 4,078	$ 3,707	$ 4,359	$ 2,524	$ 17,938,790	$ 14,668,455	$ 14,329,889
Operating Costs and Expenses	20,830	20,376	16,919	17,555	14,573	13,020	12,530	11,355
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	(11,691)	(17,177)	(12,769)	(13,830)	(12,719)	(9,277)	(8,626)	(8,864)
Net Income (Loss) Attributable to Parent	$ (11,612)	$ (16,974)	$ (12,605)	$ (13,682)	$ (12,535)	$ (9,071)	$ (8,575)	$ (8,801)	$ (54,872,933)	$ (38,981,244)	$ (53,769,484)
NeoStem, Inc. common stockholders	$ (0.32)	$ (0.48)	$ (0.40)	$ (0.49)	$ (0.47)	$ (0.45)	$ (0.46)	$ (0.53)	$ (1.68)	$ (1.90)	$ (4.00)